Quris Closes $28 Million in Seed Round  

by Kay Aloha Villamor in January 12th, 2022

Quris, a Boston and Israel-based artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced the final close of $28 million in a seed funding round led by Welltech Ventures, with participation from iAngels, Glenrock Capital, and others.

The funding will fast-track Quris’ novel drug research and development, team expansion, and partner-building efforts as it scales to rapidly scan 100s of drug candidates to train its AI engine in its mission to revolutionize the drug development process.

Company: Quris Technologies LTD. 

Raised: $28.0M

Round: Seed Round

Funding Month: January 2022

Lead Investors: Welltech Ventures 

Additional Investors: iAngels, and GlenRock Capital

Company Website: https://www.quris.ai/

Software Category: Bio-AI Clinical Prediction Platform

About the Company: Quris is an artificial intelligence innovator that is disrupting the drug development process, aims to disrupt drug development by better predicting which drug candidates will safely work in humans – ensuring the safety and efficacy of new drugs and the repurposing and personalization of existing drugs. Quris's Bio-AI Clinical Prediction Platform better predicts which drug candidates will safely work in humans, avoiding the tremendous costs of failed clinical trials. Using Quris’ patented Chip-on-Chip technology to test thousands of known and novel drug candidates on hundreds of its genetically diverse, miniaturized patients-on-a-chip, its automated, self-training BioAI platform generates proprietary data and uses machine learning to quickly predict clinical safety and efficacy. Dual-headquartered in Boston and Israel and backed by strategic biotech and big data investors, Quris is led by a proven team of AI and medical research powerhouses who are already preparing its lead discovery for clinical testing.

Source: https://www.globenewswire.com/news-release/2022/01/11/2365224/0/en/Quris-Closes-28-Million-in-Seed-Funding-From-Top-Institutional-Investors.html

 

 


Your cart
    Checkout